Neurology and AI: finding the path through a difficult landscape
May 6th 2025
Neurological diseases, including Alzheimer’s and dementia, remain some of the most challenging areas for innovation.
However, optimism is growing. With 684 new drugs currently in development, 43% already in Phase II or III, the neurology space may soon see long-awaited breakthroughs.
One key problem is early diagnosis. By the time patients are diagnosed, diseases like Alzheimer’s are often already advanced. AI-driven screening tools, particularly those using affordable methods, could revolutionise early detection and intervention.
Real-world evidence (RWE) and improved data analytics are critical enablers in this space. By integrating AI into patient surveillance and treatment planning, the life sciences sector could not only slow disease progression but potentially prevent it altogether. “Screening using AI will revolutionise the healthcare and wellbeing of people,” said one panellist. at a recent CCO round table.
“Screening using AI will revolutionise the healthcare and wellbeing of people,”
The future could also see the rise of multi-agent AI models, which integrate diverse data types for more accurate diagnosis and treatment suggestions. While breakthroughs are still on the horizon, the groundwork is being laid now.
Are you seeking a trusted partner to support your executive search in Life Sciences?
We bring decades of executive search experience and a proven track record of success across our dedicated sectors. Our investor clients rely on us time and again to build exceptional leadership teams that drive growth and deliver results.
